Johnson & Johnson Negotiates $20 Billion Sale of DePuy Synthes Orthopedics Unit to Apollo Global Management
Here's what it means for you.
This potential divestiture could reshape the healthcare investment landscape, impacting market dynamics and growth strategies.
What happened
Johnson & Johnson is in exclusive negotiations to sell its DePuy Synthes orthopedics business to Apollo Global Management for approximately $20 billion.
The Context
- Strategic Shift: J&J aims to focus on higher-growth areas like oncology and immunology, moving away from slower-growing segments like orthopedics.
- Revenue Impact: The DePuy Synthes unit generated $9.3 billion in revenue in 2025, representing less than 10% of J&J's total revenue.
- Ongoing Talks: Discussions are preliminary and non-binding, with the possibility of other bidders or a spin-off structure still on the table.
The Number
— This figure highlights the significant revenue generated by the DePuy Synthes unit, underscoring its importance in J&J's overall portfolio and the stakes involved in the potential sale.
Takeaway
If completed, this deal could mark one of the largest private equity transactions in healthcare, influencing future investment strategies in the sector.
U.S. business news, corporate developments, and economy.
"The Wall Street Journal is respected for deep financial and economic reporting with a center-right editorial perspective."
— A47 Editor
J&J Is in Talks to Sell Its Hips-and-Knees Business to Apollo for $20 Billion
Johnson & Johnson (J&J) is reportedly in discussions to sell its DePuy Synthes unit, which focuses on hips and knees, to Apollo Global Management for approximately $20 billion. This strategic move aims to allow J&J to concentrate on higher-growth sec...
Market-moving headlines impacting equities, bonds, and related risk assets.
"Real-time catalysts and volatility drivers across indices and sectors."
— A47 Editor
J&J orthopedics unit draws Apollo interest in potential $20 billion deal, Bloomberg News reports
Apollo Global Management is reportedly in negotiations to acquire Johnson & Johnson's orthopedics unit for nearly $20 billion, a move that could significantly reshape the healthcare investment landscape. This potential deal highlights Apollo's strate...
U.S. company headlines: M&A, product launches, legal/regulatory actions, and leadership moves.
"U.S.-centric corporate tape; good for tracking single-name catalysts."
— A47 Editor
Apollo in talks to buy J&J orthopedics unit for nearly $20 billion - Bloomberg
Apollo Global Management is reportedly in negotiations to acquire Johnson & Johnson's orthopedics unit for nearly $20 billion, a move that could significantly reshape the healthcare investment landscape. This potential acquisition aligns with Apollo'...